Libby Edward N, Becker Pamela S, Burwick Nicholas, Green Damian J, Holmberg Leona, Bensinger William Ira
University of Washington School of Medicine - Medical Oncology, 825 Eastlake Ave E, Seattle, WA 98109, USA.
Expert Rev Hematol. 2015 Feb;8(1):9-18. doi: 10.1586/17474086.2015.983065. Epub 2014 Nov 20.
Multiple myeloma is an incurable often devastating disease that is responsible for 1-2% of all cancers. Multiple myeloma is the second most common hematologic malignancy. Over the past two decades, advances in therapy have doubled life expectancy. Unfortunately, all patients ultimately relapse. Novel agents (immunomodulatory drugs and proteasome inhibitors) have changed the outlook for patients, but further breakthroughs are needed. Epigenetic treatments offer potential for advancing therapy by modifying oncogene responses. The acetylation status of various proteins can affect the availability of chromatin for transcription. This response may be modulated epigenetically to advantage using histone deacetylase inhibitors like panobinostat.
多发性骨髓瘤是一种无法治愈且往往具有毁灭性的疾病，占所有癌症的1% - 2%。多发性骨髓瘤是第二常见的血液系统恶性肿瘤。在过去二十年中，治疗进展使预期寿命延长了一倍。不幸的是，所有患者最终都会复发。新型药物（免疫调节药物和蛋白酶体抑制剂）改变了患者的前景，但仍需要进一步突破。表观遗传治疗通过改变癌基因反应为推进治疗提供了潜力。各种蛋白质的乙酰化状态会影响染色质用于转录的可用性。使用如帕比司他这样的组蛋白去乙酰化酶抑制剂，可以通过表观遗传方式调节这种反应以获得优势。
